Cargando…
Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative organism of COVID-19. Since this disease is considered new and does not have an approved curative protocol, many researchers have tackled the possible options for COVID-19 prevention and therapeutic approaches. We address...
Autores principales: | AbouSamra, Mona Mahmoud, Mansy, Soheir Said |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tabriz University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675919/ https://www.ncbi.nlm.nih.gov/pubmed/36415639 http://dx.doi.org/10.34172/apb.2022.067 |
Ejemplares similares
-
Adjunctive Use of Statins for COVID-19
por: Sathekge, Mike, et al.
Publicado: (2021) -
Comparison between refractive outcomes of femtosecond laser-assisted cataract surgery and standard phacoemulsification
por: Shaheen, Mohamed Shafik, et al.
Publicado: (2020) -
Adjunctive Therapies in ARDS: The Disconnect Between Clinical Trials and Clinical Practice
por: Qadir, Nida, et al.
Publicado: (2020) -
Nanolipogel Loaded with Tea Tree Oil for the Management of Burn: GC-MS Analysis, In Vitro and In Vivo Evaluation
por: Kamel, Rabab, et al.
Publicado: (2022) -
Functional assessment of early retinal changes in diabetic patients without clinical retinopathy using multifocal electroretinogram
por: Mohammed, Mai A., et al.
Publicado: (2020)